Literature DB >> 31666967

CRISPR'd babies: human germline genome editing in the 'He Jiankui affair'.

Henry T Greely1.   

Abstract

The world was shocked in Nov. 25, 2018 by the revelation that He Jiankui had used clustered regularly interspaced short palindromic repeats ('CRISPR') to edit embryos-two of which had, sometime in October, become living babies. This article is an effort to provide some deep context for the He Jiankui affair and to begin analyzing it. It focuses on He's experiment, without delving into the broader ethical issues around 'human germline genome editing' in the abstract. It begins by carefully defining 'human germline genome editing'. It then describes the little we know about the experiment before providing background on CRISPR, the pre-He ethical and legal status of human germline genome editing, and on He himself. The fourth, and longest, section provides a detailed narrative of the revelation of the He experiment and its fallout. The fifth section critiques the experiment, which I believe merits unequivocal condemnation on several grounds. The last section suggests some important immediate reactions, by 'Science' and by China.
© The Author(s) 2019. Published by Oxford University Press on behalf of Duke University School of Law, Harvard Law School, Oxford University Press, and Stanford Law School.

Entities:  

Keywords:  CRISPR; Germline genome editing; He Jiankui; assisted reproduction; ethics; eugenics

Year:  2019        PMID: 31666967      PMCID: PMC6813942          DOI: 10.1093/jlb/lsz010

Source DB:  PubMed          Journal:  J Law Biosci        ISSN: 2053-9711


  16 in total

Review 1.  Application of CRISPR/Cas System in the Metabolic Engineering of Small Molecules.

Authors:  Rajveer Singh; Shivani Chandel; Arijit Ghosh; Dhritiman Dey; Rudra Chakravarti; Syamal Roy; V Ravichandiran; Dipanjan Ghosh
Journal:  Mol Biotechnol       Date:  2021-03-27       Impact factor: 2.695

2.  CRISPR-Cas9 and He Jiankui's Case: an Islamic Bioethics Review using Maqasid al-Shari'a and Qawaid Fighiyyah.

Authors:  Nimah Alsomali; Ghaiath Hussein
Journal:  Asian Bioeth Rev       Date:  2021-03-20

3.  Towards Better Governance on Biosafety and Biosecurity: China's Advances and Perspectives in Medical Biotechnology Legislation.

Authors:  Yang Xue; Lijun Shang
Journal:  Front Bioeng Biotechnol       Date:  2022-07-04

4.  Toward Anticipatory Governance of Human Genome Editing: A Critical Review of Scholarly Governance Discourse.

Authors:  John P Nelson; Cynthia L Selin; Christopher T Scott
Journal:  J Responsible Innov       Date:  2021-07-29

Review 5.  Responsible Translational Pathways for Germline Gene Editing?

Authors:  Bryan Cwik
Journal:  Curr Stem Cell Rep       Date:  2020-08-21

Review 6.  The genome editing revolution: review.

Authors:  Ahmad M Khalil
Journal:  J Genet Eng Biotechnol       Date:  2020-10-29

7.  A CRISPR view of the 2020 Nobel Prize in Chemistry.

Authors:  Katherine E Uyhazi; Jean Bennett
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

Review 8.  Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.

Authors:  Joel Henrique Ellwanger; Bruna Kulmann-Leal; Valéria de Lima Kaminski; Andressa Gonçalves Rodrigues; Marcelo Alves de Souza Bragatte; José Artur Bogo Chies
Journal:  Virus Res       Date:  2020-05-30       Impact factor: 3.303

9.  Gene editing and CRISPR in the clinic: current and future perspectives.

Authors:  Matthew P Hirakawa; Raga Krishnakumar; Jerilyn A Timlin; James P Carney; Kimberly S Butler
Journal:  Biosci Rep       Date:  2020-04-30       Impact factor: 3.840

Review 10.  CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future.

Authors:  Fathema Uddin; Charles M Rudin; Triparna Sen
Journal:  Front Oncol       Date:  2020-08-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.